Compare Glenmark Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SANOFI INDIA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SANOFI INDIA GLENMARK PHARMA/
SANOFI INDIA
 
P/E (TTM) x 11.9 35.1 34.0% View Chart
P/BV x 1.7 6.1 27.8% View Chart
Dividend Yield % 0.6 1.4 40.0%  

Financials

 GLENMARK PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
SANOFI INDIA
Dec-18
GLENMARK PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs7126,840 10.4%   
Low Rs4844,630 10.4%   
Sales per share (Unadj.) Rs349.61,203.1 29.1%  
Earnings per share (Unadj.) Rs32.8165.3 19.8%  
Cash flow per share (Unadj.) Rs44.3209.9 21.1%  
Dividends per share (Unadj.) Rs2.0084.00 2.4%  
Dividend yield (eoy) %0.31.5 22.8%  
Book value per share (Unadj.) Rs198.6963.6 20.6%  
Shares outstanding (eoy) m282.1723.03 1,225.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.8 35.9%   
Avg P/E ratio x18.234.7 52.5%  
P/CF ratio (eoy) x13.527.3 49.3%  
Price / Book Value ratio x3.06.0 50.5%  
Dividend payout %6.150.8 12.0%   
Avg Mkt Cap Rs m168,625132,078 127.7%   
No. of employees `00012.03.3 364.6%   
Total wages/salary Rs m20,5614,068 505.4%   
Avg. sales/employee Rs Th8,196.08,393.8 97.6%   
Avg. wages/employee Rs Th1,708.11,232.4 138.6%   
Avg. net profit/employee Rs Th768.51,153.0 66.6%   
INCOME DATA
Net Sales Rs m98,65527,708 356.1%  
Other income Rs m2,081897 232.0%   
Total revenues Rs m100,73628,605 352.2%   
Gross profit Rs m15,8586,235 254.3%  
Depreciation Rs m3,2591,027 317.3%   
Interest Rs m3,3467 47,798.6%   
Profit before tax Rs m11,3356,098 185.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7562,292 163.9%   
Profit after tax Rs m9,2503,806 243.0%  
Gross profit margin %16.122.5 71.4%  
Effective tax rate %33.137.6 88.2%   
Net profit margin %9.413.7 68.3%  
BALANCE SHEET DATA
Current assets Rs m66,96815,922 420.6%   
Current liabilities Rs m40,2116,235 644.9%   
Net working cap to sales %27.135.0 77.6%  
Current ratio x1.72.6 65.2%  
Inventory Days Days8364 130.9%  
Debtors Days Days8121 389.1%  
Net fixed assets Rs m33,3227,539 442.0%   
Share capital Rs m282230 122.7%   
"Free" reserves Rs m55,77021,962 253.9%   
Net worth Rs m56,05222,192 252.6%   
Long term debt Rs m35,7380-   
Total assets Rs m132,88829,839 445.3%  
Interest coverage x4.4872.1 0.5%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.70.9 79.9%   
Return on assets %9.512.8 74.2%  
Return on equity %16.517.2 96.2%  
Return on capital %17.827.5 64.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,9987,587 830.3%   
Fx outflow Rs m22,8597,145 319.9%   
Net fx Rs m40,140442 9,081.4%   
CASH FLOW
From Operations Rs m13,2423,739 354.2%  
From Investments Rs m-6,990-731 956.2%  
From Financial Activity Rs m-7,387-1,972 374.6%  
Net Cashflow Rs m-2,9711,036 -286.8%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 6.9 14.4 47.9%  
FIIs % 34.4 14.6 235.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.5 100.0%  
Shareholders   56,727 15,184 373.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   WOCKHARDT  FULFORD INDIA  PROCTER & GAMBLE HEALTH  BIOCON   UNICHEM LAB  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - BIOCON COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS